Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Antibiotics Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 21
Figure 7. Primary Drivers and Impact Factors of North America Antibiotics Market 23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26
Figure 10. Primary Restraints and Impact Factors of North America Antibiotics Market 27
Figure 11. Investment Opportunity Analysis 31
Figure 12. Porter’s Fiver Forces Analysis of North America Antibiotics Market 34
Figure 13. Breakdown of North America Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39
Figure 14. North America Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%) 39
Figure 15. North America Antibiotics Market: Cephalosporin, 2019-2030, $ mn 40
Figure 16. North America Antibiotics Market: Penicillin, 2019-2030, $ mn 41
Figure 17. North America Antibiotics Market: Macrolides, 2019-2030, $ mn 42
Figure 18. North America Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn 43
Figure 19. North America Antibiotics Market: Quinolones, 2019-2030, $ mn 44
Figure 20. North America Antibiotics Market: Monobactam, 2019-2030, $ mn 45
Figure 21. North America Antibiotics Market: Aminoglycosides, 2019-2030, $ mn 46
Figure 22. North America Antibiotics Market: Carbapenem, 2019-2030, $ mn 47
Figure 23. North America Antibiotics Market: Other Drug Classes, 2019-2030, $ mn 48
Figure 24. Breakdown of North America Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50
Figure 25. North America Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%) 50
Figure 26. North America Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn 51
Figure 27. North America Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn 52
Figure 28. North America Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn 53
Figure 29. North America Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn 54
Figure 30. North America Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn 55
Figure 31. North America Antibiotics Market: Other Mechanisms, 2019-2030, $ mn 56
Figure 32. Breakdown of North America Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58
Figure 33. North America Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%) 58
Figure 34. North America Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn 59
Figure 35. North America Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn 60
Figure 36. North America Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn 61
Figure 37. Breakdown of North America Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63
Figure 38. North America Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%) 63
Figure 39. North America Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn 64
Figure 40. North America Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn 65
Figure 41. Breakdown of North America Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 67
Figure 42. North America Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%) 67
Figure 43. North America Antibiotics Market: Oral Administration, 2019-2030, $ mn 68
Figure 44. North America Antibiotics Market: Intravenous Administration, 2019-2030, $ mn 69
Figure 45. North America Antibiotics Market: Other Administration Routes, 2019-2030, $ mn 70
Figure 46. Breakdown of North America Antibiotics Market by Drug Type, 2019-2030, % of Revenue 71
Figure 47. North America Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%) 72
Figure 48. North America Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn 73
Figure 49. North America Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn 74
Figure 50. Breakdown of North America Antibiotics Market by Country, 2019 and 2030, % of Revenue 76
Figure 51. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 77
Figure 52. U.S. Antibiotics Market, 2019-2030, $ bn 79
Figure 53. Rising Incidence of Infectious Disease in U.S. 79
Figure 54. Canada Antibiotics Market, 2019-2030, $ bn 82
Figure 55. Antibiotics Market in Mexico, 2015-2030, $ bn 84
Figure 56. Growth Stage of North America Antibiotics Industry over the Forecast Period 86
North America antibiotics market is expected to grow by 2.3% annually in the forecast period and reach $14.67 billion by 2030 driven by rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic. Highlighted with 26 tables and 56 figures, this 116-page report “North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country. Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cephalosporin • Penicillin • Macrolides • Fluoroquinolones • Quinolones • Monobactam • Aminoglycosides • Carbapenem • Other Drug Classes Based on Action Mechanism, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Route of Administration, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Intravenous Administration • Other Administration Routes Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More